Oncologic Outcome of Robot-Assisted Laparoscopic Prostatectomy in the High-Risk Setting

Jason D. Engel, M.D.,1 William M. Kao, M.D.,1 Y. Mark Hong, M.D.,1 and Stephen B. Williams, M.D.2

Abstract

Background and Purpose: Previous studies have demonstrated the feasibility of open radical prostatectomy in the high-risk setting. Management of high-risk disease with robot-assisted laparoscopic radical prostatectomy (RALP) is controversial. We examined biochemical recurrence in a selected cohort of high-risk patients who were undergoing RALP.

Patients and Methods: Men with high-risk prostate cancer who underwent bilateral nerve-sparing, nonsalvage RALP by a single surgeon without adjuvant or neoadjuvant therapy of any kind were identified. High risk was defined by preoperative prostate-specific antigen (PSA) level $>$10 ng/dL, Gleason score $\geq$8 on final pathologic evaluation, or stage $\geq$pT3. Postoperative PSA value $\geq$0.2 ng/dL defined biochemical recurrence.

Results: A total of 73 men were identified. There was no significant difference in surgical margin positivity (38% overall) or prostate size between recurrence and nonrecurrence cohorts. Biochemical failure was significantly associated with higher pathologic Gleason score ($P = 0.0085$) but not pathologic stage ($P = 0.22$) or preoperative PSA level ($P = 0.18$). With follow-up to 85 months (mean 31.8 mos), biochemical recurrence-free survival was 77% with mean time to recurrence of 7.7 months. Recurrence occurred significantly earlier than later ($P < 0.001$).

Conclusions: Reasonable short- to intermediate-term biochemical outcomes can be achieved in a recurrence-prone group of high-risk men who are undergoing RALP. RALP is feasible in a selected cohort of high-risk men who are undergoing aggressive local therapy.

Introduction

Management of high-risk prostate cancer continues to be controversial in several areas. The optimal treatment modality for locally advanced prostate cancer has not been established, yet men are much more likely to undergo a nonsurgical therapy, such as external beam radiation therapy (EBRT), for aggressive local control.1,2 This reflects an inherent bias against radical prostatectomy (RP) as a treatment option for high-risk prostate cancer that has persisted for decades.3 Even if RP is performed, the landscape is further clouded by whether surgery alone is sufficient or whether multimodal therapy, including androgen deprivation therapy (ADT) and/or EBRT, is necessary. At the same time, the optimal definition of “high-risk” prostate cancer has not been firmly established. A recent study used eight different definitions of high-risk prostate cancer to determine oncologic outcomes after RP,4,5 highlighting the difficulty of standardizing a high-risk label.

Without randomized, controlled clinical trials, we are unlikely to find definitive answers to the management of RP in the high-risk setting. Several contemporary studies have demonstrated acceptable long-term oncologic and functional outcomes of open RP in high-risk prostate cancer, however.4,6–9 These studies have shown that RP either alone or as part of multimodal therapy (usually with ADT) has an overall survival in the 70% range at 10 years.

None of these studies specifically examined the use of robot-assisted laparoscopic prostatectomy (RALP). Approved by the United States Food and Drug Administration for RP in 2001, use of the Da Vinci radical prostatectomy grew by 30% in 2008 with 73,000 RALPs performed worldwide in 2008.10 Clearly, there is a need to further characterize the outcomes of RALP, a procedure that now accounts for an estimated two of every three RPs performed in the United States.10 There is concern about the use of RALP because of lack of tactile feedback,11 which would be particularly relevant for high-risk prostate cancer. Therefore, we evaluated the feasibility of RALP as primary, unimodal therapy in high-risk prostate cancer patients.

Patients and Methods

From an Institutional Review Board-approved, prospectively maintained database, men with high-risk prostate cancer who underwent RALP from 2002 to 2008 by a single experienced surgeon were identified. We excluded men who received adjuvant or neoadjuvant therapy of any kind. We also

1Department of Urology, George Washington University Hospital, Washington, D.C.
2Division of Urology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts.
excluded men who underwent non-nerve-sparing RALP or salvage RALP. High-risk prostate cancer was defined as a prostate-specific antigen (PSA) level >10 ng/dL, final pathologic Gleason score ≥8, or final pathologic stage ≥pT3. Pathologic staging was used to define high-risk cancer to eliminate bias from downstaging of clinical T3 or higher tumors on final pathologic determination. Clinical staging included serum metabolic chemistries, PSA levels, digital rectal examination, bone scan, and CT of the abdomen and pelvis in most cases.

RALP was performed intraperitoneally with a running vesicourethral anastomotic suture. Bilateral, interfascial nerve-sparing procedures were performed in all patients in this series. Frozen sections were liberally used to verify questionable margins. Limited lymph node dissections were performed bilaterally but were not performed if patients’ preoperative risk was low according to established preoperative guidelines. All prostate specimens were serially sectioned and processed at a single facility, with a positive surgical margin rate was 38%, with 58% of men overall having evidence of extracapsular extension on final pathologic determination and 25% with seminal vesicle invasion. Eighty-two percent had multifocal disease and 4% had positive lymph nodes, although lymph node dissections were not uniformly performed on all patients. No intraoperative or postoperative complications were noted.

Characteristics of biochemical recurrence vs nonrecurrence cohorts are listed in Table 2. There was no statistically significant difference in positive surgical margins between the two groups. There was also no significant difference in prostate size, extracapsular extension, seminal vesicle invasion, or tumor multifocality between the two cohorts. Biochemical failure was significantly associated with higher pathologic Gleason score (P = 0.0085) but not pathologic stage (P = 0.22) or preoperative PSA level (P = 0.18). Biochemical recurrence occurred significantly earlier than later (P < 0.001, Fig. 1).

With follow-up to 85 months (mean 31.8 mos), biochemical recurrence-free survival was 77% with a mean time to recurrence of 7.7 months.

### Results

A total of 73 men met our inclusion criteria (Table 1). Mean age was 61 years (range 52–74). Racial distribution was 51 (72%) white men, 18 (25%) black men, and 2 (3%) other. Average prostate gland size was 54 g. Overall positive surgical margin rate was 38%, with 58% of men overall having evidence of extracapsular extension on final pathologic determination and 25% with seminal vesicle invasion. Eighty-two percent had multifocal disease and 4% had positive lymph nodes, although lymph node dissections were not uniformly performed on all patients. No intraoperative or postoperative complications were noted.

**Table 1. High-Risk Eligibility Criteria**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Number (N)</th>
<th>Percentage (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>Stage ≥pT3a</td>
<td>76</td>
<td>100</td>
</tr>
<tr>
<td>Gleason score ≥8</td>
<td>76</td>
<td>100</td>
</tr>
<tr>
<td>PSA &gt;10 ng/dL</td>
<td>24</td>
<td>33</td>
</tr>
<tr>
<td>Patients with one factor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage ≥pT3a</td>
<td>9</td>
<td>12</td>
</tr>
<tr>
<td>Gleason score ≥8</td>
<td>12</td>
<td>16</td>
</tr>
<tr>
<td>PSA &gt;10 ng/dL</td>
<td>9</td>
<td>12</td>
</tr>
<tr>
<td>Patients with two factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage ≥pT3a + Gleason score ≥8</td>
<td>26</td>
<td>36</td>
</tr>
<tr>
<td>Stage ≥pT3a + PSA &gt;10 ng/dL</td>
<td>3</td>
<td>4</td>
</tr>
<tr>
<td>Gleason ≥8 + PSA &gt;10 ng/dL</td>
<td>6</td>
<td>8</td>
</tr>
<tr>
<td>Patients with three factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage ≥pT3a + Gleason score ≥8 + PSA &gt;10 ng/dL</td>
<td>9</td>
<td>12</td>
</tr>
</tbody>
</table>

PSA = prostate-specific antigen.
therapy than RP. Similarly, using a Surveillance, Epidemiology, and End Results sample, Denberg and colleagues showed that by 2001, 70% of high-risk prostate cancer patients were receiving aggressive local therapy, but EBRT was 6.5 times more common than RP. Of concern, 23% of men aged <70 years in 2001 had no therapy for local control while only 16% underwent RP. In addition, over the study period from 1995 to 2001, RP use declined by half from 18% to 9%.1

Early studies of RP for locally advanced prostate cancer noted poor outcomes, such as a 29% actuarial cancer-specific survival at 10 years for poorly differentiated cancers in one study encompassing 298 men from 1970 to 1993.13 This may have influenced the perception that potential cure with RP did not outweigh the side effects of surgery. Several contemporary studies, however, have shown acceptable oncologic outcomes up to 15 years. The Mayo Clinic has long advocated the role of RP in high-risk disease.14 With a median follow-up of 10.3 years in a group of 842 men with cT3 disease who were treated at Mayo Clinic, Ward and coworkers reported 7-year cancer-specific and overall survival rates of 90% and 77% in the advanced group and 99% and 88% in the baseline cohort for future comparison of high-risk patients undergoing RALP during which, if there is no recurrence in the high-risk patient, he may not have recurrence later. While it is impossible to predict the long-term biochemical outcomes of our cohort, others have shown that of all high-risk men in whom relapse occurs, 75% have relapse within 2 years after surgery across eight different definitions of high-risk prostate cancer. Therefore, we can speculate that if a high-risk man in our RALP series did not have recurrence early, he has a reasonable chance to enjoy 10-year survival rates as stated in other series.

Our study represents a unique, complete sample set in that all patients underwent RALP with a single experienced surgeon using the same technique with bilateral nerve-sparing procedures in every patient. All pathologic specimens were processed under one protocol, and follow-up was 100%, including all PSA measurements performed with the same assay. Many would consider bilateral nerve-sparing RALP to be a prohibitively “high-risk” procedure in high-risk patients, particularly given the lack of tactile feedback with RALP. We therefore specifically sought out the high-risk men most likely to have recurrence in our database—namely, those who had received bilateral nerve-sparing surgery and had not received any adjuvant or neoadjuvant therapies, such as EBRT or ADT.

Our findings suggest that even in this selected, prone-to-recurrence group, reasonable short- to intermediate-term biochemical recurrence-free survival can be achieved with bilateral nerve-sparing RALP alone. We are not advocating bilateral nerve-sparing RP as a standard procedure in high-risk men but rather show that in our selected series, short-term recurrence rates were similar to contemporary high-risk open RP series, despite bilateral nerve sparing. We have also shown that if men are to experience recurrence, they are more likely to have recurrence very soon in their postoperative course. This has implications for the timing of adjuvant multimodal therapy in that, if a high-risk patient does not have recurrence early in the postoperative period, it may be reasonable to not immediately initiate adjuvant therapy. These findings coincide with other studies in the open prostatectomy literature. Finally, our study establishes a baseline cohort for future comparison of high-risk patients undergoing RALP who did not receive any kind of neoadjuvant or adjuvant therapy.

Our findings must be interpreted in the context of the study design. First, our follow-up at a mean of 32 months is relatively short. In other contemporary open RP-only series for high-risk prostate cancer, a sharp drop-off in the first 12 months of biochemical recurrence-free survival is seen with a leveling off out to 60 months. While we cannot say whether RALP and open RP are equivalent in terms of biochemical outcomes for high-risk disease, emerging data report similar 5-year biochemical outcomes of RALP compared with open RP for organ-confined disease. Positive surgical margin rates have also been used as a surrogate outcome measure, and our 38% positive margin rate compares favorably with those reported for open RP in high-risk patients, which range from 38% to 56%.

FIG. 1. Recurrence-free survival after robot-assisted laparoscopic prostatectomy for high-risk prostate cancer.
Another potential limitation is our use of a relatively low PSA level cutoff for high-risk inclusion. The number of patients included as a result of a PSA level >10 was half that of those included because of high-risk pathologic stage or Gleason score, however; those included in the study because of a high PSA level alone comprised just 9% of the cohort (Table 1). This is in accordance to other investigators’ findings that in the PSA screening era, the nature of high-risk patients has changed such that Gleason score is more likely and PSA level less likely to determine “high-risk” prior to local therapy.16,21 Finally, while D’Amico risk categories22 are the most widely used classification for high-risk prostate cancer, we sought to use a clinically meaningful definition which included pathological data and PSA >10 ng/dl. Other investigators have suggested that any particular definition of high-risk prostate cancer has little impact on biochemical relapse-free survival variation.23

Conclusion

Men with high-risk prostate cancer who are undergoing RALP have similar short- to intermediate-term biochemical outcomes and associations to preoperative variables as those previously described for open RP. RALP is feasible in a selected cohort of men who are undergoing aggressive local therapy for high-risk prostate cancer.

Disclosure Statement

Dr. Engel is an investigator for Spectrum Pharma. For Drs. Kao, Hong, and Williams, no competing financial interests exist.

References


Address correspondence to:

Stephen B. Williams, M.D.
Division of Urology
Brigham and Women’s Hospital
Harvard Medical School
75 Francis St
Boston, MA 02115

E-mail: swilliams22@partners.org
<table>
<thead>
<tr>
<th>Abbreviations Used</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADT</td>
<td>androgen deprivation therapy</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>EBRT</td>
<td>external beam radiation therapy</td>
</tr>
<tr>
<td>PSA</td>
<td>prostate-specific antigen</td>
</tr>
<tr>
<td>RALP</td>
<td>robot-assisted laparoscopic prostatectomy</td>
</tr>
<tr>
<td>RP</td>
<td>radical prostatectomy</td>
</tr>
</tbody>
</table>

HIGH-RISK ROBOT-ASSISTED LAPAROSCOPIC PROSTATECTOMY
AU1: Oncological outcomes following robotic radical prostatectomy (RARP) in patients D'Amico high risk prostate cancer…. Please check title of Abstract.